Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Plasma cell 1CNS 1Breast 1

Conditions

Recurrence 1Multiple Myeloma 1Lung Neoplasms 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cyclophosphamide 908Carboplatin 785Paclitaxel 739pembrolizumab 738Cisplatin 707Bevacizumab 705Gemcitabine 619Docetaxel 578Rituximab 548Radiotherapy 539Dexamethasone 510Nivolumab 485Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 357Pemetrexed 334Cytarabine 334Oxaliplatin 333Lenalidomide 327Prednisone 326fludarabine phosphate 315Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Has results × Maintenance × Clear all
NCT05051631 2025-08-28

BRAVE

Vanderbilt University Medical Center

Phase NA Completed
1,071 enrolled 11 charts
Breast

Breast Neoplasms

NCT03690869 2025-04-08

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Regeneron Pharmaceuticals

Phase 1/2 Terminated
57 enrolled 31 charts
CNS

Diffuse Intrinsic Pontine Glioma, Glioma, Recurrence, Central Nervous System Neoplasms

NCT02027428 2020-08-17

Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer

Celgene

Phase 3 Completed
427 enrolled 29 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT00580372 2016-09-20

UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma

University of Arkansas

Phase 2 Completed
231 enrolled 6 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡